Tarsus Pharmaceuticals announced the pricing of an underwritten public offering of 2,812,500 shares of its common stock at a pu...

Tarsus also intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of its co...

Goldman Sachs analyst Andrea Tan maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Neutral and raises the price target f...

HC Wainwright & Co. analyst Oren Livnat maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price t...

Barclays analyst Balaji Prasad maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Overweight and raises the price target ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

Oppenheimer analyst Francois Brisebois reiterates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform and raises the pric...

Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(1.31) per share which beat the analyst consensus estimate o...

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on rev...